Skip to content
HowShorted

SELLAS Life Sciences Group, Inc. short interest in 2025

In 2025, SELLAS Life Sciences Group, Inc.'s disclosed short interest ran from 12.79% of shares outstanding on 15 Jan 2025 to 34.70% on 31 Dec 2025, a change of +21.91 percentage points. The year's high was 34.70% on 31 Dec 2025 and its low 8.49% on 30 Apr 2025, averaging 19.79% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.36 days on 15 Aug 2025. Full history: SELLAS Life Sciences Group, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for SELLAS Life Sciences Group, Inc. in 2025

2025 in figures

Start of year
12.79% (15 Jan 2025)
End of year
34.70% (31 Dec 2025)
Change
+21.91 pp
High
34.70% (31 Dec 2025)
Low
8.49% (30 Apr 2025)
Average
19.79%
Highest days to cover
19.36 (15 Aug 2025)
SEC filings marked
8

Every report in 2025

SELLAS Life Sciences Group, Inc. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 202512.79%6.00
31 Jan 202513.93%1.25
14 Feb 202512.29%3.45
28 Feb 202511.09%6.28
14 Mar 202511.15%8.76
31 Mar 20259.00%9.2410-K filed, results (8-K)
15 Apr 20258.56%6.77
30 Apr 20258.49%4.11
15 May 20259.64%3.3410-Q filed, results (8-K)
30 May 202513.45%3.62
13 Jun 202520.80%8.04
30 Jun 202526.81%5.56
15 Jul 202530.53%7.81
31 Jul 202529.07%12.33
15 Aug 202527.69%19.3610-Q filed, results (8-K)
29 Aug 202527.87%13.55
15 Sep 202519.84%11.02
30 Sep 202521.89%9.59
15 Oct 202523.83%7.19
31 Oct 202527.51%4.73
14 Nov 202522.32%8.9010-Q filed, results (8-K)
28 Nov 202523.35%10.24
15 Dec 202528.41%7.07
31 Dec 202534.70%4.31

See also: SELLAS Life Sciences Group, Inc.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.